Aegis Therapeutics is a drug-delivery and drug-formulation technologies company commercializing its patented drug delivery and protein stabilization technologies through product specific licenses to leading pharmaceutical and biopharmaceutical companies.

Intravail News

NEURELIS ANNOUNCES ACQUISITION OF AEGIS THERAPEUTICS, A LEADING DRUG DELIVERY TECHNOLOGY COMPANY

SAN DIEGO, CA – December 3, 2018 — Neurelis, Inc. today announced the acquisition of Aegis Therapeutics, a San Diego-based drug delivery technology company. Aegis Therapeutics’ proprietary portfolio includes Intravail®, ProTek® and Hydrogel™, three non-invasive drug delivery and stabilization technologies applicable to a wide-range of molecules including therapeutic proteins, peptides, non-peptide macromolecules and small molecules.

Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

SANTA MONICA, Calif., and HEMEL HEMPSTEAD, United Kingdom, Sept. 10, 2018 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc.(“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, and Consort Medical plc (“Consort”) (LSE: CSRT), a leading contract development and manufacturing organization, today announced a development and manufacturing agreement for Opiant’s OPNT003 (intranasal […]

Neurelis Files New Drug Application With The FDA For VALTOCO™ Nasal Spray, An Investigational Treatment For Pediatric, Adolescent And Adult Epilepsy Patients

SAN DIEGO, Sept. 25, 2018 /PRNewswire/ — Neurelis, Inc. today announced that the company has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for VALTOCO™ (diazepam nasal spray) as a treatment for epilepsy patients six years and older who experience increased bouts of seizure activity, also known as cluster […]

Aegis Expands its International and US Intravail® Patent Portfolio on Multiple Fronts

SAN DIEGO, CA August 2, 2018/NASDAQ — Aegis Therapeutics LLC announced today that it has been awarded European Patent No. EP2381773(B1) and Canadian Patent No. 2,748,268, providing fast acting formulations for triptans, a class of drugs that are effective in treating migraine headaches which include sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan. Human clinical […]

Dr. Reddy’s Laboratories and its U.S. subsidiary Promius Pharma announce the filing of an NDA for its migraine candidate

HYDERABAD, India & PRINCETON, N.J.–(EON: Enhanced Online News)–Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and its subsidiary, Promius Pharma, LLC today announced the filing of New Drug Application (NDA) for its migraine candidate DFN-02 with the U.S. Food and Drug Administration (USFDA).  “Acute migraine attacks are typically associated with pain and symptoms, […]

Opiant’s Intravail-based Nalmefene Provides Faster and Longer Treatment of Opioid Overdose

SANTA MONICA, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced positive data from a Phase I clinical study of its product candidate OPNT003 (intranasal nalmefene), and provided an update on a meeting held February 8, 2018 with the U.S. Food […]

Aegis Announces Breakthrough in Non-Invasive, Rapid Onset, Acute Pain Control

SAN DIEGO, CA  Oct. 10, 2017/MarketWire – Aegis Therapeutics has developed a metered nasal spray   formulation of hydromorphone having rapid onset of drug action (approximately 1 min. with a Tmax of 7.5 min.) and high systemic bioavailability (approaching 100%) based upon Aegis’ patented Intravail® technology. These formulations offer the best pharmacokinetic performance of any non‐IV […]

Opiant Pharmaceuticals, Inc. Announces Phase I Data for OPNT002 in Development for the Treatment of Alcohol Use Disorder

SANTA MONICA, Calif., July 19, 2017 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today announced results from a Phase 1 trial of OPNT002, an intranasally dosed (IN) formulation of the opioid antagonist naltrexone hydrochloride (naltrexone), in development for the treatment of Alcohol […]